141 studies found for:    Open Studies | Interleukin
Show Display Options
Rank Status Study
1 Not yet recruiting Interleukin-2—Induced Cognitive/Affective Symptoms
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Melanoma;   High-dose Interleukin-2
Intervention:
2 Not yet recruiting Interleukin-1 Blockade in HF With Preserved EF
Conditions: Heart Failure;   Preserved Ejection Fraction
Interventions: Drug: Anakinra;   Drug: Placebo
3 Recruiting Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Rilonacept;   Drug: Placebo
4 Unknown  Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices
Conditions: Diabetes;   Interleukins;   Cytokines
Intervention: Procedure: laparoscopic gastric bypass plus omentectomy
5 Recruiting Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
6 Recruiting Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Intervention: Drug: Interleukin-2
7 Unknown  Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation
Condition: Immunodeficiency Secondary to Organ Transplantation
Intervention: Procedure: transplantation
8 Recruiting Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: IL-2;   Drug: Interferon Alpha-2b
9 Unknown  Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Condition: Hepatitis C
Intervention: Genetic: Interleukin 28B genotype
10 Not yet recruiting A Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11
Condition: Chemotherapy-induced Thrombocytopenia
Intervention: Drug: mIL-11
11 Recruiting Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity
Conditions: Lipodystrophy;   Obesity;   Type 2 Diabetes
Intervention:
12 Not yet recruiting Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase I-II Study of Safety and Activity of Low Dose Interleukin-2
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Placebo;   Drug: 0.5 MIU IL-2 per day;   Drug: 1.0 MIU IL-2 per day;   Drug: 2.0 MIU IL-2 per day
13 Recruiting Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Condition: Neuroblastoma
Intervention: Drug: 3F8 Monoclonal Antibody Combined with Interleukin-2
14 Recruiting Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium
Conditions: Rheumatoid Arthritis;   Periodontitis
Intervention: Other: oral exam and
15 Recruiting Fosaprepitant for Nausea and Vomiting During High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Renal Cell Carcinoma
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Fosaprepitant
16 Not yet recruiting "Re-Stimulated" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs);   Biological: Interleukin-2
17 Recruiting Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)
Condition: Acute Myeloid Leukemia
Intervention:
18 Not yet recruiting Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor-Infiltrating Lymphocytes;   Biological: Low-Dose Interleukin
19 Recruiting Interleukin-1 Blockade in Recently Decompensated Heart Failure
Condition: Heart Failure
Interventions: Drug: Anakinra (weeks 1-2);   Drug: Anakinra (weeks 3-12)
20 Recruiting Interleukin-2 in Metastatic Melanoma
Condition: Melanoma Metastatic
Intervention: Drug: Interleukin-2

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years